Lilly And Daiichi Bet On Premium Price For Effient Over Plavix
Executive Summary
Lilly and Daiichi Sankyo's newly approved platelet inhibitor Effient (prasugrel) will be priced at an 18 percent premium to Bristol-Myers Squibb's market leader Plavix, even though Effient carries a "black box" warning for bleeding risks, the drug makers disclosed on July 15
You may also be interested in...
Effient Labeling Could Give Edge Against Plavix Through Pharmacogenetics
Lilly/Daiichi Sankyo's prasugrel has carefully constructed label to control risk of bleeding - but it also includes a pharmacogenetic argument that Effient works in clopidogrel non-responders.
Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.
Affymax's Share Price Stumbles On Questionable Phase III Hematide Data
Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.